{"id":"W2790105191","doi":"10.1200/jco.2018.36.4_suppl.209","title":"KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Sorafenib; Internal medicine; Tolerability; Discontinuation; Hepatocellular carcinoma; Oncology; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Adverse effect; Gastroenterology; Progressive disease; Surgery; Clinical trial; Immunotherapy; Phases of clinical research; Disease; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004932454,0.0002383055,0.0004219369,0.000216405,0.0002019996,0.0002900538,0.0001894262,0.0002679417,0.004070744],"category_scores_gemma":[0.0004546213,0.0001093789,0.0003040869,0.0003139707,0.000113263,0.000243785,0.0001799552,0.0003678425,0.0007322046],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004708861,"about_ca_system_score_gemma":0.0004873624,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005435756,"about_ca_topic_score_gemma":0.00177469,"domain_scores_codex":[0.9998765,0.00004769458,0.00001654921,0.00002019146,0.00001849003,0.00002058689],"domain_scores_gemma":[0.9998246,0.00003277468,0.00006079331,0.000005180304,0.00001265448,0.00006409173],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1205347,0.003609527,0.1445962,0.005638719,0.001400137,0.005142167,0.0002996196,0.001024366,0.02798145,0.0004470322,0.03760666,0.6517194],"study_design_scores_gemma":[0.08740173,0.08402213,0.6962119,0.00128578,0.002008545,0.02139156,0.0002930124,0.003304788,0.009279797,0.0006964416,0.09403222,0.00007202779],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.934241,0.04672523,0.0007057944,0.002122243,0.0002521565,0.001073406,0.002413089,0.0001498163,0.01231719],"genre_scores_gemma":[0.9899595,0.005126304,0.0005560262,0.0006643051,0.0001486414,0.0002575759,0.001587484,0.000007112849,0.001693002],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004070744,"threshold_uncertainty_score":0.01361805,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04166315873030817,"score_gpt":0.3684097563228039,"score_spread":0.3267465975924957,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}